FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company’s headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles PlatiauZURICH (Reuters) – Novartis is laying off 400 people and closing a U.S. gene therapy location that it bought only two years ago to make its $2.1 million per patient treatment